Abstracts tagged "Biologics"

Abstract Number: 2853 • 2015 ACR/ARHP Annual Meeting
Secukinumab Improves Skin Symptoms and Physical Functioning Compared with Ustekinumab in Patients with Moderate to Severe Psoriasis with Concomitant Psoriatic Arthritis: Subanalysis of a Randomized, Double Blind, Parallel-Group, Active Comparator-Controlled Phase 3b Trial
Alice B. Gottlieb¹, Diamant Thaci², Andrew Blauvelt³, Marina Milutinovic⁴ and Shephard Mpofu⁴, ¹Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ²Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany, ³Research Excellence & Personalized Patient Care, Oregon Medical Research Center, Portland, OR, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Psoriatic arthritis (PsA) is a common comorbidity in patients (pts) with psoriasis. In the ongoing Phase 3b CLEAR study (NCT02074982), secukinumab, a fully human…
Abstract Number: 617 • 2015 ACR/ARHP Annual Meeting
Biological Down-Titration in RA: Patient Profile and Response to Retreatment in Flaring Patients
Juan P. Vinicki¹, Miguel Arredondo¹, Esther Ramirez², Ana M. Ortiz Garcia³, Santos Castañeda⁴, Alberto Morell¹, Rosario Garcia-Vicuña³ and Jose María Alvaro-Gracia⁴, ¹Unidad de Terapias Biológicas, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²Farmacia, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁴Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain
Background/Purpose: Down-titration of biological therapy (BT) in rheumatoid arthritis (RA) patients with a good clinical response is frequently applied in daily clinical practice. An important…
Abstract Number: 2052 • 2015 ACR/ARHP Annual Meeting
Lymphoma in Patients with Rheumatoid Arthritis Treated with Biologic Drugs: Long-Term Follow-up of Risks and Lymphoma Subtypes
Karin Hellgren¹, Christer Sundström², Johan Askling³, Eva Baecklund⁴ and on behalf of the ARTIS study group, ¹Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute at Karolinska University Hospital, Stockholm, Sweden, ²Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden, ³Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁴Rheumatology, Department of Medical Sciences, University Hospital, Uppsala, Sweden
Background/Purpose: The long-term lymphoma risk in patients with rheumatoid arthritis (RA) treated with biologic disease modifying anti-rheumatic drugs (bDMARDs) remains a concern. The aim of…
Abstract Number: 2903 • 2015 ACR/ARHP Annual Meeting
Late-Onset Neutropenia Following Rituximab Treatment in Patients with Systemic Lupus Erythematosus
Ioannis Parodis, Frida Söder, Ronald F. van Vollenhoven, Elisabet Svenungsson and Iva Gunnarsson, Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The incidence and clinical consequences of rituximab-mediated late-onset neutropenia (LON) have been studied in various diseases, but data from Systemic Lupus Erythematosus (SLE) are…
Abstract Number: 50 • 2015 ACR/ARHP Annual Meeting
Characteristics and Outcomes Associated with Early Corticosteroid Use in a Large Multicenter Canadian RA Cohort
Kathleen Andersen¹, Daming Lin², Susan J. Bartlett^3,4, Gilles Boire⁵, Boulos Haraoui⁶, Carol Hitchon⁷, Shahin Jamal⁸, Edward C. Keystone⁹, Janet E. Pope¹⁰, Diane Tin¹¹, J Carter Thorne¹², VP Bykerk^13,14 and CATCH Investigators, ¹Hospital for Special Surgery, New York, NY, ²Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁴Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Institut de Rhumatologie, Montreal, QC, Canada, ⁷Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁸Vancouver Coastal Health, Vancouver, BC, Canada, ⁹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Toronto, ON, Canada, ¹³Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁴Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada
Background/Purpose: Synthetic glucocorticoids (steroids) are commonly used in RA to rapidly inhibit pro-inflammatory cytokines. They are frequently used as "bridge therapy", quickly dampening down the…
Abstract Number: 705 • 2015 ACR/ARHP Annual Meeting
Sex Differences in Psoriatic Arthritis: Evaluation of a Real-Life Cohort of 2,118 Italian Patients Treated with Methotrexate
Carlo Selmi^1,2, Elena Generali³, Greta Carrara⁴, Carlo Alberto Scirè⁴ and RECORD Study Group of the Italian Society for Rheumatology, ¹BIOMETRA Department, University of Milan, Milan, Italy, ²Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano, Italy, ³Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano (MI), Italy, ⁴Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy
Background/Purpose: The influence of sex in psoriatic arthritis (PsA) features and treatment outcomes has not been fully elucidated. We investigated the differences between sexes in…
Abstract Number: 2058 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Rituximab Biosimilar Candidate (CT-P10) and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase I Randomized Controlled Trial over 72 Weeks
Dae-Hyun Yoo¹, Won Park², Chang-Hee Suh³, Seung-Cheol Shim⁴, Slawomir Jeka⁵, Fidencio Cons Molina⁶, Pawel Hrycaj⁷, Wolfgang Spieler⁸, Piotr Wiland⁹, Jan Brzezicki¹⁰, Eun Young Lee¹¹, Francisco G. Medina-Rodriguez¹², Pavel Shesternya¹³, Sebastiao Radominski¹⁴, Marina Stanislav¹⁵, Volodymyr Kovalenko¹⁶, Donghyuk Sheen¹⁷, Leysan Myasoutova¹⁸, Mie Jin Lim¹⁹, Jung-Yoon Choe²⁰, Taek S. Kwon²¹ and Sang Joon Lee²¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ⁴Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ⁵University Hospital Nr 2 Dr. Jan Biziel, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Clinic of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, ⁶Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁷Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ⁸Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁹Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ¹⁰Wojewodzki Szpital Zespolony w Elablagu, Elblag, Poland, ¹¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ¹²Rheumatology, LaSalle University, Mexico City, Mexico, ¹³Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹⁴CETI-Centro de estudos em Terapias Inovadoras, Universidade Federal do Parana, Curitiba, Brazil, ¹⁵Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia, ¹⁶Section of Non-coronarogenic Myocardial Diseases and Clinical Rheumatology, National Scientific Center, Kiev, Ukraine, ¹⁷Rheumatology, Eulji University Hospital, Daejeon, South Korea, ¹⁸City Reumatology Center, Research Medical Complex Vashe Zdorovie, Kazan, Russia, ¹⁹Division of Rheumatology, Departments of Internal Medicine, Inha University Hospital, Incheion, South Korea, ²⁰Internal Medicine, Catholic University of Daegu, School of Medicine, Daegu, South Korea, ²¹CELLTRION, Inc., Incheon, South Korea
Background/Purpose: CT-P10 is a biosimilar candidate of innovator rituximab (RTX). PK profile and clinical data up to week 24 has been reported at ACR 20131.…
Abstract Number: 3171 • 2015 ACR/ARHP Annual Meeting
Combination Therapy with Denosumab and Biologic DMARD Associated with Higher Risk of Serious Infections Compared to Denosumab Alone and Biologic DMARD Alone
Ivana Parody¹, Luis Arias-Urdaneta², Ricardo Garcia Alemany² and Carlos Sesin², ¹Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL, ²Vanguard Rheumatology Partners, Miami Beach, FL
Background/Purpose: Patients with RA and other rheumatologic disorders are at increased risk for osteoporotic fractures. Biologic DMARDs are an important treatment option for these patients.…
Abstract Number: 127 • 2015 ACR/ARHP Annual Meeting
Potential Use of Healthcare Databases for Post-Marketing Surveillance Registry: an Example Using Ustekinumab
Huifeng Yun¹, Shuo Yang², Fenglong Xie³, Lang Chen⁴, Kevin L. Winthrop⁵ and Jeffrey R. Curtis⁴, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Oregon Health and Science University, Portland, OR
Background/Purpose: Underreporting and inherent deficiencies are common using spontaneous reports for post-marketing surveillance. The U.S. Food and Drug Administration (FDA) has recommended sponsors to collect…
Abstract Number: 732 • 2015 ACR/ARHP Annual Meeting
Decreased Disease Activity and Corticosteroid Usage and Improved Quality of Life during Belimumab Treatment in Patients with Systemic Lupus Erythematosus – a Prospective Real-Life Observational Study
Ioannis Parodis¹, Christopher Sjöwall², Andreas Jönsen³, Agneta Zickert¹, Martina Frodlund², Daniel Ramsköld¹, Anders A. Bengtsson³ and Iva Gunnarsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology/AIR, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ³Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden
Background/Purpose: Belimumab is the first biologic drug approved to treat Systemic Lupus Erythematosus (SLE). The efficacy of belimumab has been demonstrated through 2 phase III…
Abstract Number: 2141 • 2015 ACR/ARHP Annual Meeting
Risk of Cancer in Non-TNFi Biologics-Treated RA
Hjalmar Wadström¹, Johan Askling² and the ARTIS study group, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ²Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Immune incompetence may lower host surveillance against incipient tumours. Conversely, immune therapies have emerged as a promising therapeutic approach to cancer. Malignancies thus constitute…
Abstract Number: 3222 • 2015 ACR/ARHP Annual Meeting
Repeated Administration of Dapirolizumab Pegol (DZP) Appears Safe and Well Tolerated in Patients with Systemic Lupus Erythematosus (SLE) and Is Accompanied By an Improvement in Disease Activity: Results from a Phase 1 Study
Chris Chamberlain¹, Murray Urowitz^2,3, Julie Soranson¹, Mark Watling¹, Peter Colman¹, Olivier Harari¹, Thomas Dorner⁴ and Falk Hiepe⁴, ¹UCB Pharma, Slough, United Kingdom, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: CD40 ligand (CD40L) regulates interactions between T cells, B cells, and antigen presenting cells. Considerable evidence suggests CD40L blockade might provide an effective treatment…
Abstract Number: 139 • 2015 ACR/ARHP Annual Meeting
One-Year Cost of Etanercept, Adalimumab, and Infliximab per Treated Patient with Chronic Inflammatory Arthritides in US Veterans
Brian Sauer¹, Chia-Chen Teng², Tao He³, Jianwei Leng⁴, Chao-Chin Lu⁵, Jessica Walsh⁶, Neel Shah⁷, David J. Harrison⁸, Derek Tang⁹ and Grant W. Cannon¹⁰, ¹IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁴Internal Medicine Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁶Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁷1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA, ⁸Amgen Inc., Thousand Oaks, CA, ⁹Amgen, Inc., Thousand Oaks, CA, ¹⁰Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: Understanding the relative cost of tumor necrosis factor inhibitors (TNFi) can improve resource allocation from a payer’s perspective. Limited data exists in the VA…
Abstract Number: 890 • 2015 ACR/ARHP Annual Meeting
Anti-IgE Monoclonal Antibody in Refractory and/or Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss): Data from 17 Patients
Marie Jachiet¹, Maxime Samson², Vincent Cottin³, Jean-Emmanuel Kahn⁴, Guillaume Le Guenno⁵, Philippe Bonniaud⁶, Laurence Bouillet⁷, Anne Gondouin⁸, Fatma Makhlouf⁷, Nadine Meaux Ruault⁹, Helder Gil⁸, Hervé Devilliers¹⁰, Boris Bienvenu¹¹, André Coste¹², Violaine Giraud¹³, Stephane Dominique¹⁴, Bertrand Godeau¹⁵, Xavier Puéchal¹⁶, Chahéra Khouatra¹⁷, Marc Ruivard¹⁸, Claire Le Jeunne¹⁹, Luc Mouthon²⁰, Loïc Guillevin²¹ and Benjamin Terrier¹⁶, ¹Dermatology, Cochin Hospital, Paris, France, ²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³Division of Pneumology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon 1, Lyon, France, ⁴Internal Medicine, Foch Hospital, Suresnes, France, ⁵Internal Medicine department, Clermont-Ferrand, France, ⁶CHU, Dijon, France, ⁷CHU, Grenoble, France, ⁸CHU, Besancon, France, ⁹Internal Medicine and Clinical Immunology, CHU de Besançon, Besançon, France, ¹⁰Department of Internal Medicine and Systemic Diseases, Dijon University Hospital, Dijon, France, ¹¹Internal Medicine, Hospital Caen, Caen, France, ¹²CHI, Créteil, France, ¹³Hôpital Ambroise Paré, Boulogne Billancourt, France, ¹⁴Pneumology, Rouen University Hospital, Rouen, France, ¹⁵Henri Mondor, Créteil, France, ¹⁶Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ¹⁷CHU Lyon, Lyon, France, ¹⁸CHU Clermont-Ferrand, Clermont–Ferrand, France, ¹⁹Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, ²⁰Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, ²¹Internal Medicine, Hopital Cochin, Paris, France
Background/Purpose: Omalizumab, an anti-IgE monoclonal antibody, has proven efficacy for the treatment of moderate-to-severe and severe-persistent allergic asthma and allergic rhinitis, with a favorable safety…
Abstract Number: 2316 • 2015 ACR/ARHP Annual Meeting
An Ethnographic Observational Study of the Biologic Initiation Conversation Between Rheumatologists and Biologic Naïve Rheumatoid Arthritis Patients
Nicholas Kottak¹, Melissa Rosenberg², Dennis Parenti³ and Shelly Kafka³, ¹Ethnographic Solutions, Washington, DC, ²Janssen Pharmaceuticals Inc, Horsham, PA, ³Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: To better understand how rheumatologists communicate the need to initiate biologic treatment and explain the risks and benefits, Janssen Pharmaceuticals initiated an ethnographic market…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].